Statera Biopharma Receives Positive Nasdaq Listing Determination20221027210314
Statera Biopharma Receives Positive Nasdaq Listing Determination
October 27, 2022
Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF20221021214443
Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam’s Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients20221017193504
Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K20221006221411
Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K
October 6, 2022
Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency20220909235256
Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq20220825213329
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing20220523200615